Interview with the CEO and CTO of CPTx, Hendrik Dietz and Christian Sigl
Preclinical Stage
2025-05-13T07:05:39.000Z
The CTO of CPTx, Christian Sigl is talking about their revolutionary platform technology centered on creating DNA nanostructures.
CPTx’s current focus is the infectious disease space, creating a therapeutic platform to neutralize virus infections, starting with influenza. The company is building nanometer sized backbone that are armed with a virus-binding molecule to trap and neutralize virus particles making them incapable of infecting other cells.
Read the Bioneex Story with CPTx